Tempus AI
Precision medicine company pairing genomic tests with AI: Tempus One clinical assistant, Loop target discovery, and a multimodal oncology data platform
Overview
Tempus AI works on "precision oncology with AI-driven insights": it runs genomic tests such as xT (a 648-gene DNA panel) and the FDA-approved xT CDx, and turns the resulting clinical and molecular data into AI products. Tempus One is an AI clinical assistant that gives providers fast answers about a patient's clinical and molecular profile and serves researchers as a hub for Tempus data; Loop (April 2025) is an oncology target discovery and validation platform combining real-world data, patient-derived models and CRISPR screens with AI; olivia is a consumer app that pulls records from 1,000+ health systems and summarizes them with AI. Founded in 2015 by Eric Lefkofsky and based in Chicago, Tempus listed on Nasdaq in June 2024, bought Ambry Genetics and Paige in 2025, agreed to buy Personalis in July 2026, and reported $382.5M revenue for Q2 2026.
The Verdict
Who Should Use Tempus?
Best For
- Oncologists who order genomic testing and want AI help reading the results
- Pharma and biotech teams that license real-world oncology data
- Drug discovery teams looking for AI-backed target validation
Not Ideal For
- Anyone looking for a self-serve AI tool with a price list
- Investors or buyers who want AI revenue separated from lab testing revenue
What's Great
- Large multimodal oncology dataset built from its own testing business
- Revenue up 22% year over year in Q2 2026, with Data and Applications up 28%
- Acquisitions add digital pathology (Paige) and hereditary testing (Ambry)
Watch Out For
- Most revenue still comes from diagnostics, not AI software
- A short-seller report claimed AI apps were a small slice of 2024 revenue
- No public pricing; products are sold to providers, payers and pharma
Pricing
View all features & details
Products
- xT and xT CDx genomic profiling
- Tempus One AI clinical assistant
- Loop target discovery platform (Apr 2025)
- Next: closing gaps in care
- olivia patient app (national launch Jan 2025, iOS and Android)
Company
- Founder: Eric Lefkofsky; HQ Chicago
- IPO priced June 2024 at $37 per share
- Acquired Ambry Genetics ($600M, Feb 2025) and Paige (Aug 2025)
- FY2026 revenue guidance $1.595B to $1.605B
How It Compares
| Feature | Tempus AI | Owkin |
|---|---|---|
| Core business | Genomic testing plus AI and data | AI agents for biopharma R&D |
| Main AI product | Tempus One clinical assistant | K Pro AI scientist |
| Free access | No public free tier for clinicians | K Pro free tier on public datasets |
| Public company | Yes (Nasdaq) | No |
Sources: Loop launch · olivia launch (Jan 2025) · IPO Scoop · Owkin K Pro
Is this your tool? Add a badge